Joshua F Baker1, Andrew Stokes2, Sofia Pedro3, Ted R Mikuls4, Michael George5, Bryant R England4, Harlan Sayles4, Fred Wolfe3, Kaleb Michaud6. 1. Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia. 2. Boston University School of Public Health, Boston, Massachusetts. 3. FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas. 4. VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha. 5. University of Pennsylvania, Philadelphia. 6. FORWARD, The National Databank for Rheumatic Diseases, Wichita, Kansas, and VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska.
Abstract
OBJECTIVE: The present study was undertaken to evaluate whether the rate of incident chronic opioid use is higher in obese patients with rheumatoid arthritis (RA). METHODS: Participants with RA in the FORWARD databank were asked about their use of weak and strong opioid medications on semiannual surveys. Incident chronic opioid use was defined as new reported use extending over 2 contiguous surveys (~7-12 months). Cox proportional hazards models were used to evaluate associations between body mass index (BMI) at enrollment and incident chronic opioid use (overall use and strong opioid use). Models adjusted for demographics, smoking, disease duration, RA treatments, household income, and education level. The predicted 5-year cumulative incidence was calculated from Cox models. RESULTS: Among 19,794 participants, 2,802 experienced an incident episode of chronic opioid use over 93,254 person-years of follow-up. Higher BMI was associated with higher risk of chronic opioid use. Severe obesity (BMI >35 kg/m2 ) was associated with a higher risk of overall use (adjusted hazard ratio [HRadj ] 1.74 [95% confidence interval (95% CI) 1.72-2.04], P < 0.0001) and strong opioid use (HRadj 2.11 [95% CI 1.64-2.71], P < 0.001) compared to normal BMI. This association was partially explained by greater comorbidity, pain, and disability in obese groups. The attributable risk for obesity was 15% of overall opioid use and 24% of strong opioid use. CONCLUSION: Obesity is associated with a substantially higher risk of incident chronic opioid use. Approximately 1 in 4 cases of incident use of strong opioids may be attributable to obesity, suggesting a major public health impact. Interventions to prevent or reduce obesity could have an important impact on the use of opioids.
OBJECTIVE: The present study was undertaken to evaluate whether the rate of incident chronic opioid use is higher in obese patients with rheumatoid arthritis (RA). METHODS: Participants with RA in the FORWARD databank were asked about their use of weak and strong opioid medications on semiannual surveys. Incident chronic opioid use was defined as new reported use extending over 2 contiguous surveys (~7-12 months). Cox proportional hazards models were used to evaluate associations between body mass index (BMI) at enrollment and incident chronic opioid use (overall use and strong opioid use). Models adjusted for demographics, smoking, disease duration, RA treatments, household income, and education level. The predicted 5-year cumulative incidence was calculated from Cox models. RESULTS: Among 19,794 participants, 2,802 experienced an incident episode of chronic opioid use over 93,254 person-years of follow-up. Higher BMI was associated with higher risk of chronic opioid use. Severe obesity (BMI >35 kg/m2 ) was associated with a higher risk of overall use (adjusted hazard ratio [HRadj ] 1.74 [95% confidence interval (95% CI) 1.72-2.04], P < 0.0001) and strong opioid use (HRadj 2.11 [95% CI 1.64-2.71], P < 0.001) compared to normal BMI. This association was partially explained by greater comorbidity, pain, and disability in obese groups. The attributable risk for obesity was 15% of overall opioid use and 24% of strong opioid use. CONCLUSION: Obesity is associated with a substantially higher risk of incident chronic opioid use. Approximately 1 in 4 cases of incident use of strong opioids may be attributable to obesity, suggesting a major public health impact. Interventions to prevent or reduce obesity could have an important impact on the use of opioids.
Authors: J Denise Power; Anthony V Perruccio; Rajiv Gandhi; Christian Veillette; J Roderick Davey; Stephen J Lewis; Khalid Syed; Nizar N Mahomed; Y Raja Rampersaud Journal: Arthritis Care Res (Hoboken) Date: 2019-08-03 Impact factor: 4.794
Authors: Joshua F Baker; Bryant R England; Ted R Mikuls; Harlan Sayles; Grant W Cannon; Brian C Sauer; Michael D George; Liron Caplan; Kaleb Michaud Journal: Arthritis Care Res (Hoboken) Date: 2018-12 Impact factor: 4.794
Authors: Patricia Katz; Mary Margaretten; Laura Trupin; Gabriela Schmajuk; Jinoos Yazdany; Edward Yelin Journal: Arthritis Care Res (Hoboken) Date: 2016-01 Impact factor: 4.794
Authors: J H Humphreys; S M M Verstappen; H Mirjafari; D Bunn; M Lunt; I N Bruce; D P M Symmons Journal: Arthritis Care Res (Hoboken) Date: 2013-01 Impact factor: 4.794
Authors: Patrick D Quinn; Kwan Hur; Zheng Chang; Erin E Krebs; Matthew J Bair; Eric L Scott; Martin E Rickert; Robert D Gibbons; Kurt Kroenke; Brian M D'Onofrio Journal: Pain Date: 2017-01 Impact factor: 7.926
Authors: Lukas Mangnus; Wouter P Nieuwenhuis; Hanna W van Steenbergen; Tom W J Huizinga; Monique Reijnierse; Annette H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2016-10-22 Impact factor: 5.156
Authors: Austin M Wheeler; Punyasha Roul; Yangyuna Yang; Kaitlyn M Brittan; Harlan Sayles; Namrata Singh; Brian C Sauer; Grant W Cannon; Joshua F Baker; Ted R Mikuls; Bryant R England Journal: Arthritis Care Res (Hoboken) Date: 2022-04-05 Impact factor: 5.178